The Autoimmune CAR-T Race Has a New Mantra: Make It Last

The Numbers Behind the Confidence

The EULAR data gave Cabaletta some real ammunition. In its RESET-Myositis trial for dermatomyositis (a rare inflammatory muscle disease), 83% of patients hit the planned registrational endpoint at week 16 while completely off immunosuppressants. All five responders maintained that drug-free state for up to 1.5 years.

In systemic sclerosis (a disease that hardens skin and can destroy lungs), early patient data showed something unusual: responses actually kept getting stronger with longer follow-up. That's the opposite of what you'd expect from a therapy wearing off. Cabaletta was confident enough to announce a registrational study in systemic sclerosis patients with lung disease, planned for late 2026.

And then there's the lupus program, where things got genuinely surprising. Cabaletta has been testing a version of rese-cel that skips the chemotherapy "preconditioning" step (the lymphodepletion regimen that prepares the body for CAR-T cells). Even at the lowest dose, one of the first two patients showed deep B-cell depletion that looked remarkably similar to patients who'd received the full chemo prep. If that holds up, it could mean CAR-T without chemo for autoimmune patients; a massive practical advantage.

The Broader Data Backs the Thesis

Cabaletta isn't operating in a vacuum. The largest prospective autoimmune CAR-T trial, called CASTLE, treated 24 patients with severe lupus, myositis, and systemic sclerosis using a similar CD19 CAR-T approach. The overall response rate was 87.5%. Over a median follow-up of 13 months (and up to 23 months for some patients), zero relapses occurred. Every responder stayed off immunosuppressants.

That's the kind of track record that makes the "immune reset" concept feel less like marketing and more like biology.

What's Actually Different About Rese-cel

So if everyone's chasing CD19, how does Cabaletta's product stand out? Three design choices matter here.

First, rese-cel uses a fully human CD19 binder. Many CAR-T products use mouse-derived components, which can trigger the patient's immune system to attack the therapy itself. A fully human design should mean less immunogenicity and, theoretically, more time for the CAR-T cells to finish the job.

Second, the 4-1BB costimulatory domain. In oncology, CARs built with 4-1BB tend to expand more slowly but persist longer than those with CD28. For autoimmune disease, where you need sustained B-cell depletion (not a quick kill), that's a feature, not a bug.

Third, the entire program is designed for outpatient administration. Cancer CAR-T typically means a hospital stay. Cabaletta's safety profile so far has been mild enough (mostly low-grade cytokine release syndrome, with rare and resolving cases of neurotoxicity) that patients could potentially get treated and go home. That changes the economics and scalability of the whole approach.

The Stock Tells an Interesting Story

Guggenheim recently raised its target to $16 with a Buy rating. Wells Fargo is more cautious at $4. The company bolstered its balance sheet with a $100 million equity offering, giving it meaningful runway to push rese-cel into registrational trials. But this remains a clinical-stage biotech with no revenue. The market is waiting for proof that the "durability-first" strategy actually works at scale.

The Real Question Nobody Can Answer Yet

The honest caveat: nobody knows what happens at year five. The longest autoimmune CAR-T follow-up data top out around two years. Remission rates look spectacular in that window, but B cells eventually come back. Whether those new B cells stay well-behaved over a decade is still an open question.

Cabaletta is betting that by the time that answer arrives, it will have already built the most compelling durability dataset in the field. In a race where everyone has a CD19 CAR-T, the company that can prove "one and done" actually means "one and done forever" will own the market.

The subscription model of autoimmune treatment has been worth tens of billions. Replacing it won't be easy. But Cabaletta is making the case that the real disruption isn't the CAR-T cell itself; it's how long the reset holds.